CA2365326A1 - Methods of increasing bone volume using non-naturally-occurring fp selective agonists and antiresorptive compounds - Google Patents

Methods of increasing bone volume using non-naturally-occurring fp selective agonists and antiresorptive compounds Download PDF

Info

Publication number
CA2365326A1
CA2365326A1 CA002365326A CA2365326A CA2365326A1 CA 2365326 A1 CA2365326 A1 CA 2365326A1 CA 002365326 A CA002365326 A CA 002365326A CA 2365326 A CA2365326 A CA 2365326A CA 2365326 A1 CA2365326 A1 CA 2365326A1
Authority
CA
Canada
Prior art keywords
bisphosphonic acid
bone
occurring
naturally
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002365326A
Other languages
English (en)
French (fr)
Inventor
James Richard Hartke
Mark Walden Lundy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2365326A1 publication Critical patent/CA2365326A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002365326A 1999-03-05 2000-03-01 Methods of increasing bone volume using non-naturally-occurring fp selective agonists and antiresorptive compounds Abandoned CA2365326A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12292399P 1999-03-05 1999-03-05
US60/122,923 1999-03-05
PCT/US2000/005198 WO2000051617A1 (en) 1999-03-05 2000-03-01 Methods of increasing bone volume using non-naturally-occurring fp selective agonists and antiresorptive compounds

Publications (1)

Publication Number Publication Date
CA2365326A1 true CA2365326A1 (en) 2000-09-08

Family

ID=22405659

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002365326A Abandoned CA2365326A1 (en) 1999-03-05 2000-03-01 Methods of increasing bone volume using non-naturally-occurring fp selective agonists and antiresorptive compounds

Country Status (10)

Country Link
EP (1) EP1158987A1 (es)
JP (1) JP2002538122A (es)
AU (1) AU3712000A (es)
CA (1) CA2365326A1 (es)
CO (1) CO5150237A1 (es)
IL (1) IL145124A0 (es)
NO (1) NO20014193L (es)
NZ (1) NZ513827A (es)
PE (1) PE20001553A1 (es)
WO (1) WO2000051617A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024179A (en) * 1972-11-08 1977-05-17 Pfizer Inc. Substituted ω-pentanorprostaglandins
ATE114473T1 (de) * 1984-04-30 1994-12-15 Procter & Gamble Ausrüstung für die verwendung bei der behandlung von osteoporose.
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
NO20014193L (no) 2001-11-05
AU3712000A (en) 2000-09-21
NO20014193D0 (no) 2001-08-29
EP1158987A1 (en) 2001-12-05
PE20001553A1 (es) 2001-01-30
NZ513827A (en) 2001-09-28
WO2000051617A1 (en) 2000-09-08
IL145124A0 (en) 2002-06-30
JP2002538122A (ja) 2002-11-12
CO5150237A1 (es) 2002-04-29

Similar Documents

Publication Publication Date Title
US6156799A (en) Method of increasing bone volume using non-naturally-occurring FP selective agonists
US6329354B1 (en) Methods for the treatment of osteoporosis
CA2365326A1 (en) Methods of increasing bone volume using non-naturally-occurring fp selective agonists and antiresorptive compounds
RU2294203C2 (ru) Способ лечения костных нарушений
CA2199252A1 (en) Methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone
CA2366755A1 (en) Method of increasing bone volume using non-naturally-occurring ep, selective agonists
EP0779813A1 (en) Phosphonates and parathyroid hormone for osteoporosis
SK3402000A3 (en) Use of a substance primary activating the osteoblastic protein kinase c/intracellular calcium pathways of a subject
JP2002527386A (ja) 骨形成調節方法
EP1328277B1 (en) Bisphosphonic compounds for strengthening of cortical bone
WO2000051616A1 (en) Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives
CZ2000808A3 (cs) Použití selektivního FP agonisty, který se přirozeně nevyskytuje
MXPA00002395A (es) Metodo para incrementar el volumen oseo
MXPA00002394A (es) Metodo para incrementar el volumen oseo usando agonistas selectivos de prostanoide f no naturales
Liu et al. Effects of a new conjugate drug in a rat model of postmenopausal osteoporosis
Naveh-Many et al. Vitamin D analogs for the treatment of secondary hyperparathyroidism in chronic renal failure

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued